


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Hom et al. Examiner: Unknown
Serial No.: 09/816,876 Group Art Unit: 1645
Filed: March 23, 2001 Docket: 13615.1USU2
Notice of Allow. Date:
Due Date: n/a Batch No.:
Title: METHODS TO TREAT ALZHEIMER'S DISEASE

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: BOX IDS, Commissioner for Patents, Washington, D.C. 20231, on November 6, 2001.

By: 
Karen Olsen

BOX IDS
Commissioner for Patents
Washington, D.C. 20231


Sir:

We are transmitting herewith the attached:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Supplemental Information Disclosure Statement, Form 1449, 2 boxes Reference(s)
- Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: 
Name: Matthew A. Doscotch
Reg. No.: 48,957
MAD:ko





Suppl. IDS #8
JL 11/29/01

S/N 09/816,876

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HOM ET AL. Examiner: UNKNOWN
Serial No.: 09/816,876 Group Art Unit: 1645
Filed: MARCH 23, 2001 Docket No.: 13615.1USU2
Title: METHODS TO TREAT ALZHEIMER'S DISEASE

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on November 6, 2001.

By: Karen Olsen

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Applicants also maintain a CD ROM with images of these references and those references submitted on the initial Information Disclosure Statement for the convenience of the Examiner. The Examiner is requested to contact the undersigned attorney for the CD ROM and it will be sent directly to the Examiner.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or

TECH CENTER 1600/2900
NOV 28 2001

RECEIVED

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,
MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.371.5271


Date: November 6, 2001



By: Matthew A. Doscotch
Name: Matthew A. Doscotch
Reg. No. 48,957
MAD:ko

Date Mailed: 11/6/01

Sheet 1 of 7

FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number:	Application Number:
			13615.1USU2	09/816,876
			Applicant: Hom ET AL.	
Filing Date: 3/23/01	Group Art Unit: 1645			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,522,811	06/11/1985	Eppstein et al.			
	4,616,088	10/07/1986	Ryono et al.			
	4,636,491	01/13/1987	Bock et al.			
	4,665,193	05/12/1987	Ryono et al.			
	4,668,770	05/26/1987	Boger et al.			
	4,749,792	06/07/1988	Natarajan et al.			
	5,142,056	08/25/1992	Kempe et al.			
	5,175,281	12/29/1992	McCall et al.			
	5,387,742	02/07/1995	Cordell			
	5,441,870	08/15/1995	Seubert et al.			
	5,461,067	10/24/1995	Norbeck et al.			
	5,481,011	01/02/1996	Chen et al.			
	5,482,947	01/09/1996	Talley et al.			
	5,502,061	03/26/1996	Hui et al.			
	5,502,187	03/26/1996	Ayer et al.			
	5,508,294	04/16/1996	Vazquez et al.			
	5,510,349	04/23/1996	Talley et al.			
	5,510,388	04/23/1996	Vazquez et al.			
	5,516,784	05/14/1996	Bennett et al.			
	5,521,219	05/28/1996	Vazquez et al.			
	5,545,640	08/13/1996	Beaulieu et al.			
	5,593,846	01/14/1997	Schenk et al.			
	5,604,102	02/18/1997	McConlogue et al.			
	5,610,190	03/11/1997	Talley et al.			
	5,612,486	03/18/1997	McConlogue et al.			
	5,631,405	05/20/1997	Pal et al.			
	5,639,769	06/17/1997	Vazquez et al.			
	5,648,511	07/15/1997	Ng et al.			

RECEIVED
TECH CENTER 1600
NOV 28 2001


EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)				Docket Number: 13615.1USU2	Application Number: 09/816,876
				Applicant: Hom ET AL.	
				Filing Date: 3/23/01	Group Art Unit: 1645

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	TECH CENTER 1600/2900 FILING DATE IF APPROPRIATE NOV 20 2001
	5,720,936	02/24/1998	Wadsworth et al.			
	5,721,130	02/24/1998	Seubert et al.			
	5,733,882	03/31/1998	Carr et al.			
	5,744,346	04/28/1998	Chrysler et al.			
	5,753,652	05/19/1998	Fässler et al.			
	5,760,064	06/02/1998	Vazquez et al.			
	5,760,076	06/02/1998	Vazquez et al.			
	5,766,846	06/16/1998	Schlossmacher et al.			
	5,807,870	09/15/1998	Anderson et al.			
	5,811,633	09/22/1998	Wadsworth et al.			
	5,827,891	10/27/1998	Dressman et al.			
	5,830,897	11/03/1998	Vazquez et al.			
	5,847,169	12/08/1998	Nummy et al.			
	5,849,911	12/15/1998	Fässler et al.			
	5,850,003	12/15/1998	McLonlogue et al.			
	5,863,902	01/26/1999	Munoz et al.			
	5,877,015	03/02/1999	Hardy et al.			
	5,877,399	03/02/1999	Hsiao et al.			
	5,912,410	06/15/1999	Cordell			
	5,935,976	08/10/1999	Bold et al.			
	5,942,400	08/24/1999	Anderson et al.			
	5,965,588	10/12/1999	Vazquez et al.			
	6,001,813	12/14/1999	Gyorkos et al.			
	6,022,872	02/08/2000	Vazquez et al.			
	6,051,684	04/18/2000	McDonald et al.			
	6,060,476	05/09/2000	Vazquez et al.			
	6,150,344	11/21/2000	Carroll et al.			
	6,153,652	11/28/2000	Wu et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)				Docket Number: 13615.1USU2	Application Number: 09/816,876
				Applicant: Hom ET AL.	
				Filing Date: 3/23/01	Group Art Unit: 1645




TECH CENTER 1600/2900
NOV 8 2001


RECEIVED

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,191,166 B1	02/20/2001	Audia et al.			
	6,221,670 B1	04/24/2001	Cordell et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	0 609 625 A1	08/10/1994	Europe			
	0 652 009 A1	05/10/1995	Europe			
	WO 94/04492	03/03/1994	PCT			
	WO 95/06030	03/02/1995	PCT			
	WO 98/22597	05/28/1998	PCT			
	WO 00/17369	03/30/2000	PCT			
	WO 00/47618	08/17/2000	PCT			
	WO 00/56335	09/28/2000	PCT			
	WO 00/61748	10/19/2000	PCT			
	WO 00/69262	11/23/2000	PCT			
	WO 00/77030	12/21/2000	PCT			
	WO 01/00663	01/04/2001	PCT			
	WO 01/00665 A2	01/04/2001	PCT			
	WO 01/19797 A2	03/22/2001	PCT			
	WO 01/23533 A2	04/05/2001	PCT			
	WO 01/29563 A1	04/26/2001	PCT			
	WO 01/51659 A2	07/19/2001	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Alterman et al., <i>J. Med. Chem.</i> , 1998, 41, 3782-3792 Design and Synthesis of New Potent C ₂ -Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 13615.1USU2	Application Number: 09/816,876
		Applicant: Hom ET AL.	
		Filing Date: 3/23/01	Group Art Unit: 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 			
		Amblard et al., <i>J. Med. Chem.</i> , 1999, 42:20, pp. 4193-4201 Synthesis and Characterization fo Bradykinin B ₂ Receptor Agonists Containing Constrained Dipeptide Mimics	
		Balicki et al., <i>Synth. Comm.</i> , 1993, 23(22), pp. 3149-3155 Mild and Efficient Conversion of Nitriles to Amides with Basic Urea-Hydrogen Peroxide Adduct	
		Barton, <u>Protective Groups in Organic Chemistry</u> , 1976, Chpt. 2, pp. 43-93 Protection of N-H Bonds and NR	
		Basu et al., <i>Tetrahedron Letters</i> , 1998, 39, pp. 3005-3006 Efficient Transformation of Nitrile into Amide under Mild Condition	
		Bennett et al., <i>Synlett</i> , 1993, 9, pp. 703-704 The Synthesis of Novel HIV-Protease Inhibitors via Silica Gel Asisted Addition of Amines to Epoxides	
		Berge et al., <i>Journal of Pharmaceutical Sciences</i> , 1/1977, 66:1, pp. 1-19 Pharmaceutical Salts	
		Bodendorf et al., <i>The Journal of Biological Chemistry</i> , 2001, 276:15, pp. 12019 - 12023 A Splice Variant of β -Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein	
		Bose et al., <i>Synth. Comm.</i> , 1997, 27(18), pp. 3119 - 3123 A Facile Hydration of Nitriles by Dimethylidioxirane.	
		Calderwood et al., <i>Tetrahedron Letters</i> , 1997, 38:7, pp. 1241 - 1244 Organocerium Reactions of Benzamides and Thiobenzamides: A Direct Synthesis of Tertiary Carbinamines	
		Chen et al., <i>Tetrahedron -Mannaric Acid Letters</i> , 1997, 38:18, pp. 3175 - 3178 A Practical Method for the Preparation of α' -Chloroketones of N-Carbamate Protected- α -Aminoacids	
		Ciganek, <i>J. Org. Chem.</i> , 1992, 57:16, pp. 4521 - 4527 Tertiary Carbinamines by Addition of Organocerium Reagents to Nitriles and Ketimines	
		Citron et al., <i>Nature</i> , 1992, 360:6405, pp. 672-674 Mutation of the β -amyloid Precursor Protein in Familial Alzheimer's Disease Increases β -Protein Production	
		Cushman et al., <i>J. Med. Chem.</i> , 1997, 40:15, pp. 2323 - 2331 Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Groth	
		Deno, et al., <i>J. Am. Chem. Soc.</i> , 1970, 92:7, pp. 3700 - 3703 Protonated Cyclopropane Intermediates in the Ractions of Cyclopropanecarboxylic Acids	
		Diedrich et al., <i>Tetrahedron Letters</i> , 1993, 34:39, pp. 6169-6172 Stereoselective Synthesis of A Hydroxyethylene Dipeptide Isostere	
		Dovey et al., <i>Journal of Neurochemistry</i> , 2001, 76, pp. 173-181 Functional Gamma-Sec]retase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain	
		Emilien, et al., <i>Neurological Review</i> , 2000, 57, pp. 454-459 Prospects for Pharmacological Intervention in Alzheimer Disease	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 13615.1USU2	Application Number: 09/816,876
			Applicant: Hom ET AL.	
			Filing Date: 3/23/01	Group Art Unit: 1645

RECEIVED
TECH CENTER 1600/2000
NOV 28 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
		Felman et al., <i>J. Med. Chem.</i> 1992, 35:7, pp. 1183-1190 Synthesis and Antiulcer Activity of Novel 5-(2-Ethenyl Substituted)-3(2H)furanones		
		Games et al., <i>Letters to Nature</i> , 2/9/1995, 373:6514, pp. 523-527 Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F β -amyloid Precursor Protein		
		Gao et al., <i>Tetrahedron Letters</i> , 1994, 50:4, pp. 979-988 Asymmetric Hetero Diels-Alder Reaction Catalyzed by Stable and Easily Prepared CAB Catalysts		
		Ghosh et al., <i>J. Med. Chem.</i> , 1993, 36, pp. 2300-2310 Potent HIV Protease Inhibitors: The Development of Tetrahydrofurylglucines as Novel P ₃ -Ligands		
		Greene et al., <i>Protective Groups in Organic Synthesis: 2nd Ed.</i> , 1991, Chpt. 7, pp. 309-405 Protection for the Amino Group		
		Hardy, <i>Nature Genetics</i> , 1992, 1, pp. 233-234 Framing β -Amyloid		
		Heck, <i>Palladium Reagents in Organic Syntheses</i> , 1985, Chpt. 8.2, pp. 342-365 Carbonylation of Aromatic Compounds to Acids, Acid Derivatives, Aldehydes and Ketones		
		Hussain et al., <i>Molecular and Cellular Neuroscience</i> , 1999, 14, pp. 419-427 Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase		
		Kabalka et al., <i>Synth. Comm.</i> , 1990, 20(10), pp. 1445-1451 The Transformation of Nitriles into Amides		
		Kang et al., <i>Nature</i> , 1987, 325:6106, pp. 733-736 The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor		
		Kitaguchi et al., <i>Nature</i> , 2/11/1988, 331:6156, pp. 530-532 Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity		
		Klumpp et al., <i>J. Am. Chem. Soc.</i> , 1979, 101:23 Lithiation of Cyclopropylcarbinols		
		Lakouraj et al., <i>Indian Journal of Chemistry</i> , 1999, 38B, pp. 974-975 Selective Conversion of Nitriles to Amides by Amberlyst A-26 Supported Hydroperoxide		
		Lin et al., <i>PNAS</i> , 2000, 97:4, pp. 1456-1460 Human Aspartic Protease Memapsin 2 Cleaves the β -Amyloid Precursor Protein		
		Luo et al., <i>Nature Neuroscience</i> , 3/2001, 4:3, pp. 231-232 Mice Deficient in BACE1, the Alzheimer's β -secretase, have Normal Phenotype and Abolished β -amyloid Generation		
		March, <i>Advanced Organic Chemistry: Reactions, Mechanisms, and Structure</i> , 3d Ed., pp. 380-381 Aliphatic Nucleophilic Substitution		
		Mashraqui et al., <i>J. Am. Chem. Soc.</i> , 1982, 104, pp. 4461-4465 Cyclophanes. 14. Synthesis, Structure Assignment, and Conformational Properties of [2.2](2,5)Oxazolo- and Thiazolophanes		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 13615.1USU2	Application Number: 09/816,876
			Applicant: Hom ET AL.	
			Filing Date: 3/23/01	Group Art Unit: 1645

RECEIVED
NOV 28 2001
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
		McLendon et al., <i>The FASEB Journal</i> , 2000, 14:15, pp. 2383-2386 Cell-Free Assays for Gamma-Secretase Activity		
		Miyaura et al., <i>Chem. Rev.</i> , 1995, 95, pp. 2457-2483 Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds		
		Murahashi et al., <i>J. Org. Chem.</i> , 1992, 57:9, pp. 2521-2523 Ruthenium-Catalyzed Hydration of Nitriles and Transformation of 8-Keto Nitriles to Ene-Lactams		
		Norman et al., <i>J. Med. Chem.</i> , 2000, 43, pp. 4288-4312 Structure-Activity Relationships of a Series of Pyrrolo[3,2- <i>d</i>]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists		
		Owa et al., <i>J. Med. Chem.</i> , 1999, 42, pp. 3789-3799 Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle		
		Pirttila et al., <i>Neuroscience Letter</i> , 1998, 249, pp. 21-24 Longitudinal Study of Cerebrospinal Fluid Amyloid Proteins and Apolipoprotein E in Patients with Probable Alzheimer's Disease		
		Reetz et al., <i>Tetrahedron Letters</i> , 30:40, pp. 5425-5428 Protective Group Tuning in the Stereoselective Conversion of α -Amino Aldehydes into Aminoalkyl Epoxides		
		Sebti et al., <i>Tetrahedron Letters</i> , 1996, 37:36, pp. 6555-6556 Catalyse Heterogène de L'Hydratation des Nitriles en Amides par le Phosphate Naturel Dope par KF et le Phosphate Trisodique		
		Selkoe, <i>Neuron</i> , 1991, 6:4, pp. 487-498 The Molecular Pathology of Alzheimer's Disease		
		Seubert, et al., <i>Nature</i> , 9/1992, 359:6393, pp. 325-327 Isolation and Quantification of Soluble Alzheimer's β -peptide from Biological Fluids		
		Shearman et al., <i>Biochemistry</i> , 2000, 39, pp. 8698-8704 L-685, 458, an Aspartyl Protease Transition State Mimic, is a Potent Inhibitor of Amyloid β -Protein Precursor γ -Secretase Activity		
		Sinha, et al., <i>Nature</i> , 12/2/1999, 402:6761, pp. 537-540 Purification and Cloning of Amyloid Precursor Protein β -secretase from Human Brain		
		Smith et al., <i>Advanced Organic Chemistry - Reactions, Mechanisms and Structure</i> , 2001, 5ed., Chpt. 19, pp. 1552-1554 Reduction of Carboxylic Acids and Esters to Alkanes		
		Snyder et al., <i>J. Am. Chem. Soc.</i> , Jan - Jun 1938, pp. 105-111 Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids		
		Thurkauf et al., <i>J. Med. Chem.</i> , 1990, 33, 1452-1458 Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues		
		Tucker et al., <i>J. Med. Chem.</i> , 1992, 35:14, pp. 2525-2533 A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 13615.1USU2	Application Number: 09/816,876
			Applicant: Hom ET AL.	
			Filing Date: 3/23/01	Group Art Unit: 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
		Vassar et al., <i>Science</i> , 10/22/1999, 286:5440, pp. 735-741 β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE		
		Wang et al., <i>Synlett</i> , 6/2000, 6, pp. 902-904 Preparation of α-Chloroketones by the Chloroacetate Claisen Reaction		
		Werner et al., <i>Organic Syntheses</i> , 1973, Collective Vol. 5, pp. 273-276 Cyclobutylamine*		
		Wilgus, et al., <i>Tetrahedron Letters</i> , 1995, 36:20, pp. 3469-3472 The Acid-Catalyzed and Uncatalyzed Hydrolysis of Nitriles on Unactivated Alumina		
		Yan et al., <i>Nature</i> , 12/1999, 402:6761, pp. 533-537 Membrane-anchored Aspartyl Protease with Alzheimer's Diseaseβ-secretase Activity		

RECEIVED
TECH CENTER 1600/2900
NOV 28 2001



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	